CelLBxHealth has announced the publication of an independent, peer‑reviewed study demonstrating that its Parsortix platform ...

Johnson & Johnson has announced positive topline results from the phase 3 MonumenTAL‑6 study, which evaluated TECVAYLI and ...

Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...

First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...

Lundbeck has received Fast Track designation from the U.S. FDA for Lu AH69593, its lead oral orexin 2 receptor agonist in ...

There are currently no approved pharmacological treatments for cALD in the EU.

GSK has secured US FDA approval for Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1‑positive ...

Infinitopes has dosed the first patient with ITOP1, its lead investigational therapeutic cancer vaccine, marking the first ...

The CHMP has adopted a positive opinion recommending approval of Lynavoy for the treatment of cholestatic pruritus in adults ...

Atsena Therapeutics has received orphan designation from the European Medicines Agency for its two clinical‑stage gene ...

OrbusNeich has enrolled the first patient in its pivotal Japanese clinical trial evaluating its proprietary coronary ...

Nouscom will present new phase 1b/2 data on its off‑the‑shelf cancer immunotherapy NOUS‑209 at the European Society for ...